Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal�
+4.37 (2.35%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 185.01 - 190.85
52 week 113.14 - 190.85
Open 185.50
Vol / Avg. 1.81M/1.37M
Mkt cap 36.78B
P/E 79.19
Div/yield     -
EPS 2.40
Shares 198.30M
Beta 0.68
Inst. own 97%
Oct 23, 2014
Q3 2014 Alexion Pharmaceuticals Inc Earnings Call - Webcast
Oct 23, 2014
Q3 2014 Alexion Pharmaceuticals Inc Earnings Release
Sep 8, 2014
Alexion Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
Alexion Pharmaceuticals Inc at Robert W. Baird & Co. Inc Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 32.02% 16.30%
Operating margin 42.63% 34.04%
EBITD margin - 38.96%
Return on average assets 19.15% 8.53%
Return on average equity 23.74% 11.62%
Employees 1,774 -
CDP Score - -


352 Knotter Drive
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

Officers and directors

Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Stephen P. Squinto Ph.D. Chief Global Operations Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 57
Bio & Compensation  - Reuters
John B. Moriarty J.D. Senior Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 44
Bio & Compensation  - Reuters
Frank J. Wright Senior Vice President; President of Alexion Pharma International Sarl
Age: 66
Bio & Compensation  - Reuters
Leonard Bell M.D. Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
David L. Hallal Chief Operating Officer, Director
Age: 47
Bio & Compensation  - Reuters
R. Douglas Douglas Norby Lead Independent Director
Age: 78
Bio & Compensation  - Reuters